Kornimate/medical-research-clean huggingface dataset:
latinos understanding the need for adherence in diabetes using e-health

Conditions: Type 2 Diabetes; Glycemic Control; Psychological Distress

Summary: latinos understanding the need for adherence in diabetes using care coordination, integrated medical and behavioral care and e-health (luna-e) is a randomized controlled trial (rct) that will test the effectiveness a patient-centered, team-based, primary care intervention with e-health enhancements in improving glycemic control (primary outcome, hemoglobin a1c level) and psychological distress (secondary outcome; depression, anxiety symptoms).

luna-e will help advance our understanding of optimal approaches to diabetes healthcare services in a large, growing, us population at high risk for diabetes and related complications. if shown effective, luna-e has high potential for broad scaling and dissemination due to its community partnered approach, use of technology, and implementation within a large, exemplar federally qualified health center (fqhc) environment. the study's total sample size is 600, with 400 consented and enrolled in the randomized controlled trial (rct). an additional 200 participants will be identified for medical records review and will not undergo study related activities. the rct (arms 1 and 2) targets 400 latino patients with type 2 diabetes from a local fqhc pool of registered patients. the eligibility criteria are: 1) latino ethnicity of any race; 2) registered patient of fqhc; 3) \> 18 years; 4) type 2 diabetes with hemoglobin a1c (hba1c) \>7.5% in past 90 days; 5) provider approval; 6) not participating in any other diabetes intervention. biological measurements will be taken at baseline, 3-, 6-, and 12-months to detect changes in glycemic control. clinical lab measures, medication adherence, weight, health behaviors and psychosocial measures will also be obtained across the study. for arm 3,the research team will work with the fqhc it to query all patients with type 2 diabetes and then identify 200 matched controls, using propensity score matching as guided by the study statistician. selection criteria will occur after the study has completed recruitment. only de-identified data will be obtained from the medical records for these individuals. de-identified data will be provided by the fqhc it department.

Eligibility criteria:
inclusion criteria: 1. self identify as hispanic/latino ethnicity of any race 2. registered patient of federally qualified health center 3. 18 years of age or older 4. type 2 diabetes with hemoglobin a1c (hba1c) \>7.5% in past 90 days 5. approval from primary care provider 6. not currently enrolled/participating in any other diabetes intervention program(s) exclusion criteria: 1. actively being treated for cancer or parkinson's disease 2. pregnant or nursing (temporary exclusion, may qualify 6-months postpartum) 3. have plans to move out of the area in the next 12 months 4. have other existing mental or physical health problems so severe as to prohibit informed consent and participation 5. have severe diabetes complications (e.g., renal disease, or on dialysis)
effects of preoperative immunonutrition in patients undergoing pancreaticoduodenectomy

Conditions: Pancreatic Cancer; Bile Duct Cancer

Summary: the purpose of this study is to determine whether preoperative immunonutrition is effective on infectious complication and th1/th2 differentiation in patients with pancreaticoduodenectomy.

the investigators reported that preoperative immunonutrition improve the incidence of postoperative infectious complication in patients after pancreaticoduodenectomy, and modulation of th1/th2 differentiation may play important roles in this effect. object of this study is to investigate the effects preoperative immunonutrition on incidence of postoperative infectious complication, and th1/th2 balance after pancreaticoduodenectomy.

Eligibility criteria:
inclusion criteria: * patients underwent pancreaticoduodenectomy exclusion criteria: * age younger than 18 years * ongoing infection * gastrointestinal obstruction * respiratory dysfunction * cardiac dysfunction * hepatic dysfunction * renal failure * history of recent immunosuppressive or immunological diseases * preoperative evidence of widespread metastatic disease

Keywords: immunonutrition pancreaticoduodenectomy th1 th2
carboplatin-gemcitabine versus cisplatin- gemcitabine as neoadjuvant chemotherapy for treatment of muscle invasive urinary bladder cancer

Conditions: Urinary Bladder Cancer

Summary: patients will be randomized in 1:1 ratio to two treatment groups first group will receive 3-4 cycles of neoadjuvant carboplatin(auc4)-gemcitabine (treatment group) and second group will receive 3-4 cycles of neoadjuvant cisplatin(75mg/m2 day1)-gemcitabine (control group). patients will undergo radiological assessment, full laboratory work up, and cystoscopy before undergoing either radical cystectomy or definitive radiotherapy concurrent with chemotherapy

patients will be randomized in 1:1 ratio to two treatment groups first group will receive 3-4 cycles of neoadjuvant carboplatin(auc4)-gemcitabine (treatment group) and second group will receive 3-4 cycles of neoadjuvant cisplatin(75mg/m2 day1)-gemcitabine (control group). patients will undergo radiological assessment, full laboratory work up, and cystoscopy before undergoing either radical cystectomy or definitive radiotherapy concurrent with chemotherapy. after finishing treatment, all patients should undergo follow up every 3 months for two years then six monthly thereafter .follow up will include history, physical examination, full laboratory works (cbc, renal function testing and liver function testing). imaging by ct or mri abdomen and pelvis for all patients and cystoscopy in bladder preservation protocol

Eligibility criteria:
inclusion criteria:all patients diagnosed with muscle invasive urinary bladder cancer that can receive chemotherapy are included the criteria are * • age above 18 years, * pathologically proven urinary bladder cancer, * patients with clinical stages t2-4a n0-3 m0, * patients with good renal and liver functions * patients with no distant metastases, * no other malignancy (double malignancy). * performance status 0-1 according to ecog performance status scale. * patients with no contraindications for radiotherapy. exclusion criteria: * • performance status 2-4 according to ecog performance status scale. * patients refuse to receive chemotherapy, * patients not eligible to receive chemotherapy due to liver or renal impairment or thrombocytopenia, * patients with m1 disease.
transvaginal versus transabdominal extraction of laparoscopically-excised specimen

Conditions: Colorectal Neoplasms; Urologic Neoplasms; Gastrointestinal Neoplasms; Neoplasms by Site

Summary: the aim of this study is to evaluate the outcomes of transvaginal natural orifice specimen extraction (nose) in patients who are planning multiport laparoscopic surgery for resection of solid organs including kidney, liver, stomach, adrenal gland and bladder.

study design: this was a prospective, single center, single arm study. this clinical trial was approved by the institutional review boards. study process: all patients gave informed written consent after being informed of the details of the study. all participants underwent demographic and history taking, laboratory tests and a gynecological examination to determine whether specimen removal through vagina is possible. the patients who was adequate for this study were planned to perform multiport laparoscopic surgery and patients were subjected to transvaginal nose. to perform transvaginal nose procedure, the patients were placed in the lithotomy position with trendelenburg position. after about 1-2cm incision at the posterior vaginal fornix, endopouch was introduced into the abdominal cavity through vaginal incision site. the specimen was placed inside a endopouch and removed through vagina. closure of vaginal incision site was achieved by transvaginally with 2/0 absorbable suture. during the second and third visit at 1 week and 8 week, patient and observer scar assessment scale (posas) was performed to assess cosmetic outcomes of scar. subjects with sexual activity carried out female sexual function index (fsfi) questionnaire to assess sexual function at final visit which occurred at 6 months after surgery. statistical analysis: all data are summarized as means ± standard deviation or as numbers with proportions. a p \< 0.05 was considered to indicate significance. student's t-test and mann-whitney u test were conducted to compare continuous parametric variables and non-parametric variables, respectively.

Eligibility criteria:
inclusion criteria: * patients who are accessible with vaginal approach * patients scheduled for laparoscopic resection of stomach, colon, kidney and spleen for benign or malignant diseases * patients with normal cervical cancer screening tests within the last 3 years except inflammatory findings exclusion criteria: * patients without sexual intercourse * patients who are considered unable to remove specimen through vagina due to narrow introitus in gynecological examination * patients who are expected to have severe adhesion due to deep infiltrative endometriosis or previous pelvic surgery history * patients with abnormal cervical cancer screening tests * patients scheduled to perform concomitant hysterectomy

Keywords: natural orifice specimen extraction laparoscopic surgery transvaginal female
evaluation of the risk of nsf following prohance injection in patients with chronic kidney disease

Conditions: Renal Insufficiency

Summary: the objective of this long term study is to prospectively compare the incidence of nsf in two cohorts (cohort 1- patients with moderate chronic kidney disease egfr 30-59 and cohort 2- patients with severe chronic kidney disease or kidney failure egfr \<30).


Eligibility criteria:
inclusion criteria: cohort 1 * is going to receive or has received prohance injection during an mri examination; * has ckd with egfr stably comprised between 30 and 59 ml/min/1.73m2, as calculated from a scr value obtained from the local laboratory within 24 hours prior to the prohance injection. * provides written informed consent and is willing to comply with protocol requirements. or cohort 2 * is going to receive or has received prohance injection during an mri examination; * has ckd with egfr below 30 ml/min/1.73m2, as calculated from a scr value obtained from the local laboratory within 24 hours prior to the prohance injection. * provides written informed consent and is willing to comply with protocol requirements. exclusion criteria: cohort 1 * has received a gbca within the past 12 months prior to inclusion in this study; * has unstable kidney function; * has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data and achieving study objectives; * has ever been suspected of, or diagnosed with, nsf prior to the study-specific mri; * is unable or unwilling to return for necessary office visits, to be examined by dermatologists or to undergo deep skin biopsy should development of nsf be suspected. or cohort 2 * has received a gbca within the past 12 months prior to inclusion in this study; * has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data and achieving study objectives; * has ever been suspected of, or diagnosed with, nsf prior to the study-specific mri; * is unable or unwilling to return for necessary office visits, to be examined by dermatologists or to undergo deep skin biopsy should development of nsf be suspected.
safety and tolerability study of ragweed slit tablets

Conditions: Rhinitis, Allergic, Seasonal; Ragweed Pollen Allergy

Summary: the purpose of this study is to determine the safety and tolerability of several doses of ragweed pollen allergen extract administered as sublingual tablets in subjects with allergic rhinitis to ragweed.


Eligibility criteria:
inclusion criteria: * written consent * male or female subjects from 18 yo 60 years old and in general good health * for women of child bearing potential: negative urine pregnancy test and use of medically effective contraceptive method * symptoms of ragweed pollen induced allergic rhinitis for at least the last 2 years * sensitization to ragweed pollen as demonstrated with positive skin prick test to ragweed pollen and specific ige level (ragweed pollen) \> 0.70 ku/l at screening * fev1 at least of 80% of predicted value at screening exclusion criteria: * past or current disease which, as judged by the investigator, may affect the outcome of this study * history of life-threatening asthma * asthma requiring daily treatment (whatever the pharmaceutical class) * pregnant or lactating women * subjects who previously received desensitisation treatment to ragweed pollen and/or other asteraceae or who plan to start desensitisation treatment during this study * symptoms during the treatment phase due to a sensitivity to a second allergen * subjects treated with ongoing immunotherapy with another allergen

Keywords: ragweed, allergy, sublingual immunotherapy
benefits of eggs in combination with a plant-based diet

Conditions: Coronary Artery Disease; Diabetes; Metabolic Syndrome

Summary: the main objective of the study is to demonstrate that the inclusion of eggs to a plant-based diet will not increase the risk for heart disease but will increase the concentration of lutein and zeaxanthin, two important antioxidants and will also increase choline, an important component of membrane phospholipids.

results from studies involving cells, animal models and clinical trials have demonstrated that lutein and zeaxanthin potentially protect against chronic diseases, including age-related macular degeneration, cataracts, coronary heart disease and stroke. plasma concentrations of lutein and zeaxanthin are closely associated with their antioxidant properties and with their protection against reactive oxygen species (ros). choline is recognized as an essential nutrient for health because of its many functions in growth and development, as well as neurological function and formation of membrane phospholipids, including phosphatidylcholine (pc) and sphingomyelin. therefore the objective of this study is to demonstrate that inclusion of eggs in a plant-based diet will potentiate the benefits of this healthy diet by increasing plasma concentrations of lutein, zexanthin and choline presents in egg yolks and theoretically increase the antioxidant and anti-inflammatory actions of these components. this would be potentially more important in those individuals with metabolic syndrome, which is the target population of this intervention.

Eligibility criteria:
inclusion criteria: * all genders * 35-70 years * metabolic syndrome (based on 3 out of 5 characteristics: waist circumference. 88 cm for women and \> 102 cm for men; plasma triglycerides \> 150 mg/dl, blood pressure \> 135/85 mm hg, fasting glucose \> 100 mg/dl and hdl \< 40 mg/dl for men and \< 50 mg/dl for women) * willing to consume a spinach omelet made with 2 eggs or the equivalent amount of egg substitute daily for 4 weeks each * willing to follow a plant-based diet for 13 weeks * not have cardiovascular disease, high cholesterol, diabetes, cancer, liver or renal disease * proficient in english exclusion criteria: * self-reported diabetes, cardiovascular disease, history of stroke, liver disease or cancer * taking glucose lowering medications * triglycerides \> 500 mg/dl * cholesterol \> 240 mg/dl * blood pressure \> 145/100 mm hg * allergic to eggs or spinach

Keywords: eggs lutein zeaxanthin choline metabolic syndrome plant-based diet
"eye protection after mydriatic use for rop screening: impact on vitals signs and pain scores"

Conditions: Light Sensitivity

Summary: pupillary dilation induced by mydriatic agents during retinopathy of prematurity exams can persist for hours. despite regular use of eye protection for mydriatic-induced light sensitivity for infants, children and adults, eye protection after mydriasis has not been addressed in neonates. this study examines the use of eye patches to protect the dilated pupil from light exposure and their impact on vital signs and pain scores. prevents tachycardia, tachypnea and discomfort in neonates after rop screening.

pain management for retinopathy of prematurity (rop) screening focuses on pharmacological and non-pharmacological interventions during the actual eye examination. management of pain related to increased light sensitivity during the post-mydriasis period has not been described. this prospective, randomized study evaluated the impact of protecting the eyes from ambient light exposure post mydriasis. vital signs and pain scales were recorded in infants randomized to either wear or not wear eye patches after mydriasis for their rop exam. infants less than 30 weeks gestational age or less than 1500 grams at birth were included. standard statistical methods were used to compare vital signs and pain scores for each group at baseline, 1 and 3 hours after mydriasis.

Eligibility criteria:
inclusion criteria: * all infants with gestational age at birth of 30 weeks or less or with birth weight less than 1500g undergoing their first rop exam in the infant special care unit (iscu) at utmb. exclusion criteria: * infants were excluded if they had any congenital malformation or syndrome; a history of eye surgery or were receiving inotropics medications.

Keywords: pain mydriasis light
observational study of iron metabolism in anemia in icu and post-operative patients

Conditions: Anemia; Intensive Care; Cardiac Surgery

Summary: anemia in intensive care and post-operative patients is due to both blood loss (leading to iron loss) and inflammation.

anemia in intensive care and post-operative patients is due to both blood loss (leading to iron loss) and inflammation. the latter is known to interfere with iron metabolism, inducing iron storage instead of using it for hemoglobin synthesis. the discover of a new regulatory hormone of iron metabolism, hepcidin, may help us to better understand the link between inflammation and iron functional deficit. the aim of our study is to observe the variation of usual iron metabolism biological markers and of hepcidin, in order to define the better marker of iron loss in these clinical situations.

Eligibility criteria:
inclusion criteria: * anemia (haemoglobin \< 10 g/dl) * hospitalization in icu for an expected duration of 7 days or more * or, day one post cardiac surgery exclusion criteria: * chronic anemia (hb \< 9 g/dl for more than one month before hospitalization) * iron metabolism disease

Keywords: anemia intensive care cardiac surgery iron metabolism hepcidin
effect of creatine and l-arginine on endothelial function

Conditions: Coronary Artery Disease

Summary: the study is a double blind 2x2 factorial study. patients with coronary disease will be randomly be assigned to l-arginine (9 g/day), creatine 21 g/d, both, or neither dietary supplement. the function of the endothelium will be tested using ultrasound before and after each treatment. these studies will help us understand why the endothelium is abnormal in patients with coronary artery disease and how l-arginine is acting on endothelial function.


Eligibility criteria:
inclusion criteria: * coronary artery disease exclusion criteria: * pregnancy * creatine use within one month of study * l-arginine use within one month of study * change in dose or initiation of lipid lowering therapy, aspirin therapy, or angiotensin converting enzyme therapy within one month of study
relationship between postoperative delirium and heart function in valvular surgery

Conditions: Valvular Surgery

Summary: delirium is an acute brain lesion characterized by abnormalities of consciousness, attention, cognition and sensation. many brain diseases such as stroke, traumatic brain injury and intracranial hypertension can lead to cardiac insufficiency, arrhythmia and heart failure. the incidence of postoperative delirium in patients undergoing cardiac surgery is high. postoperative delirium is a manifestation of brain function injury. the effect of postoperative delirium on postoperative cardiac function in patients undergoing cardiac surgery is worthy of further discussion.


Eligibility criteria:
inclusion criteria: * patients undergoing valvular surgery * age between 60 to 75 exclusion criteria: * have a history of cerebral infarction before operation * cardiac function was seriously impaired before surgery * neuropsychiatric disorders were present before surgery
interactive studies of endstage diabetic dialysis patients

Conditions: Diabetes

Summary: the purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients. hypothesis: the expansile capacity of blood vessels is affected by different hemoglobin concentrations in diabetic hemodialysis patients.

vascular disease is an important cause of morbidity and mortality in patients with chronic kidney disease (ckd), of which a large proportion is diabetic. diabetics have complex and multiple reasons for vascular disease, and there is accumulating evidence of associated poor endothelial cell function, particularly in those with kidney disease. one important mechanism through which this might occur relates to changes in shear rate and stress resulting from different viscosity levels. such fluctuations are increasingly recognized to affect endothelial cell function and hence vessel-wall adaptability in both the short and long term. little is known of the consequence of different shear effects on endothelial cell function at various hemoglobin levels in kidney disease. there is some evidence to suggest however that, in the presence of micro-vascular disease, a relative anemia, with associated lower viscosity and shear stress, may be of benefit compared to higher hemoglobin levels. diabetics account for almost 40% of dialysis patients worldwide, and are the fastest growing component of the epidemic of ckd. thus, an understanding of optimal treatment targets for anemia therapy, and the impact of different target levels of hemoglobin on vascular wall function is imperative.

Eligibility criteria:
inclusion criteria: * diabetics and non-diabetics on hemodialysis * on erythropoietin and iron * on a statin exclusion criteria: * uncontrolled blood pressure (bp) * ulcers * amputations * unstable cardiac function * malignancy * planned operations

Keywords: vascular reactivity anemia correction therapy hemodialysis patients diabetic and non-diabetic patients diabetes in hemodialysis patients
validation of an urticaria control test

Conditions: Chronic Urticaria

Summary: the aim of this study is to validate a previously developed patient reported outcome instrument (in project uct-d) to assess disease control in chronic urticaria patients (urticaria control test - uct) of age 12 and older.


Eligibility criteria:
all patients suffering from chronic forms of urticaria are eligible

Keywords: urticaria disease control severity test